NLARx Newsletter Header
NLARx News
May 10, 2010
In This Issue
NLARx on Facebook
Save the Date
News from the States
Outrage of the Week
Pharmaceutical Pricing
Health Reform
Conflicts of Interest
Advertising & Marketing
Pharma Watch
PBM Watch
Patents & Generics
Medicare & Medicaid
Safety & Clinical Trials
Quick Links
Join Our Mailing List
NLARx on Facebook!
For up-to-the-minute posting of news of interest and events, become a fan of NLARx on Facebook here!
Save the Date!
Portland PierRegister now for our next meeting: We are meeting in conjunction with the CSG Eastern Regional Conference August 15-18. Visit beautiful Portland Maine for the latest on what states are doing to lower drug costs and implement federal health reform including changes to Medicaid rebates and the Sunshine Act. Registration and meeting details: more
Other Upcoming Conferences
14th Annual 340B Coalition Conference July 19-21, Washington DC.  For more details and to register: more
Prescription for Conflict: Should Industry Fund Continuing Medical Education? Presented by PharmedOut, June 25, Washington DC.  For more details and to register: more
Job Posting
Independent Drug Information Service - Program Director position available.  For more information please see here.
News from the States
Connecticut - Connecticut Bill To Limit Gifts To Docs Dies Quietly more
Florida -
Thousands of Florida Seniors Miss Out on Medicare Drug Help more
Maine - ME gets $1.2M in drug settlement | >>more
Utah - Utah Sues Drugmakers Over Antipsychotic Marketing | >>more
Vermont - Vermont Legislature Debates Free Samples more
Wisconsin - Wisconsinites to Keep Paying More for $4 Prescription Drugs more
Outrage of the Week - Avandia
Testimony of Sidney M. Wolfe, M.D. Director, Health Research Group at Public Citizen Before House Agriculture-FDA Appropriations Subcommittee Hearing on Rosiglitazone (Avandia) more
Pharmaceutical Pricing
US Trade Rep Criticized For Medicines Policy more
Pharma Pay Outpaces U.S. Private-Sector Wage more
Dendreon: Provenge to Cost $93K for Full Course of Treatment more
Cancer Patients' Dilemma: Expensive Pills vs. Invasive Chemo Treatment more
Biotech Industry Reviews Effects Of The Recession more
Pharmaceuticals & Health Reform
When Prescribing a Drug, Doctors Have Many Choices - Too Many in Some Cases more
Digitize Medical Records; Waiting Puts Lives at Risk more
Schools, Systems Get More Funding To Expand Electronic Medical Records more
Healthcare Overhaul May Cost Drugmakers More Than Expected more
Conflict of Interest & Disclosure
What Do Patients Want? And Why It Matters For Sunshine  more
Glaxo Tells Journal Editors To Censor Steve Nissen more
NAMI State Chapters And Pharma Funding more
The Symptom? Nervousness. The Cause? Doctors' Financial Ties more
Advertising and Marketing
Physicians Saying No More Often To Drug Reps more
Sales Reps Face Rising Tide of Inaccessible Docs more
J&J Sales Reps Must Ride With Compliance Police more
More Drug Promos Are Drawing FDA's Ire more
For $520 Million, AstraZeneca Will Settle Case Over Marketing of a Drug more
Commercial Free Speech Or Off-Label Marketing? more
Pharma Watch
Drug Makers to Pay Fine of $81 Million more
AstraZeneca Settles Drug Marketing Lawsuit, Plea Deal Rejected For Possibly Defective Heart Device Maker more
Judge's Ruling Gives 'Wide Latitude' To Plaintiffs' In Lawsuits Against Omniscan Imaging Drug more
BIO Locks Out Media From Keynote Speeches more
Harry Reid Gets Some Campaign Help From PhRMA more
J&J to Pay $81 Million, End Federal Cases on Topamax more
PBM Watch
NCPA Endorses PBM Transparency Bill more
CVS Caremark 1Q Up 4.5%, Optimistic On 2011 Selling Season more
CVS Heats Up Pharmacy Benefit Competition for Medco more
Patents and Generics
Appeals Court Upholds Pay-For-Delay Deals more
Roche Loses Patent On AIDS Drug In India more
Medicare and Medicaid
The Mystery of Medicare Part D "Cost Underruns" more
Medicare Part D's Exclusion of Benzodiazepines and Fracture Risk in Nursing Homes more
Federal Officials Confirm States May Lose Some Medicaid Drug Rebate Money more
Safety and Clinical Trials
FDA Commissioner: Use Generic Alternatives to Recalled J&J Meds more
House Committee To Investigate Johnson & Johnson After Kids' Tylenol Recall more
Congress Probes J&J Over Tylenol Recall more
Johnson & Johnson Division Recalls 43 OTC Medicines for Infants and Children more
Experts, Conflicts and the F.D.A. more
FDA Critics Say Controversy About Diabetes Drug Points To Need For Agency Changes more
The Pfizer Geodon Trial And Physician Mishaps more